| Management target | Revenue 18.6% FY27 |
|---|
| Revenue growth | 31.34% YoY in Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 28.1%; full-year target stabilized at 20%. |
| Demand visibility | Steady orders across domestic markets; expanding IP-grade pharma base. |
| Management confidence | High on long-term sustainable growth and Kronox integration synergies. |
Growth
Revenue rose 31.34% to ₹70.36 Cr; EBITDA up 62.16% to ₹19.8 Cr; PAT increased 59.31% to ₹16.25 Cr.
Outlook
FY27 guidance: ₹250-260 Cr revenue with 20% EBITDA margin. Planned ₹50 Cr capex for Boron Oxide/Boric Acid expansion.
Risks
Q2 seasonality (monsoon), volatile raw material costs due to war, and potential margin compression vs Q1 peaks.
Last quarter's promises, checked
Delivered
- Guided FY26 Revenue ~₹215 Cr → delivered ₹215.45 Cr (= BEAT)
- Guided DOT sales 1,500 tons → delivered ~1,500 tons target track (= BEAT)
- Guided 20-21% EBITDA margin → delivered 28.1% in Q1 FY27 (= BEAT)
Partly delivered
- Guided Boron Oxide launch in 3-4 quarters → In progress/Capex stage (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: INDOBORAX. Summary written with AI assistance from the document.
Indo Borax & Chemicals Ltd: key numbers
- Share price
- ₹480.00
- Market cap
- ₹1,540 Cr
- Revenue (annual)
- ₹215.4 Cr
- Net profit (annual)
- ₹50.27 Cr
- P/E (TTM)
- 27.4×Sector 37.2×
- Promoter holding
- 38.41%+7.61% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indo Borax & Chemicals Ltd
All →Indo Borax & Chemicals Debt & Borrowing: ₹225 Cr
Indo Borax & Chemicals Ltd has availed funding of ₹225 Crore from a lending institution. The capital will finance its acquisition of equity shares in Kronox Lab Sciences Limited.
- Value
- ₹225.0 Cr
Indo Borax & Chemicals Annual General Meeting
Indo Borax & Chemicals reported postal ballot results where shareholders approved borrowing limits up to Rs 400 Crore. One special resolution passed with 98.05% in favour.
Indo Borax & Chemicals Investor Presentation: Key Takeaways
Indo Borax reported strong Q1FY27 consolidated performance with Revenue up 31% and PAT up 59% YoY. Strategy focuses on high-margin DOT expansion and the acquisition of Kronox Lab Sciences.
Indo Borax & Chemicals Credit Rating
Indo Borax & Chemicals Ltd received a credit rating update from India Ratings, placing its bank loan facilities on 'Rating Watch with Negative Implications'.
Indo Borax & Chemicals Other Announcement
Indo Borax & Chemicals Ltd. is relocating its corporate office to a new premises in Andheri (East), Mumbai, effective September 15, 2026.
Indo Borax & Chemicals Acquisition Worth ₹103.2 Cr
Indo Borax & Chemicals Limited has announced the acquisition of Kronox Lab Sciences Limited for Rs. 103.22 Crore. The cash deal aims to diversify the company's chemical portfolio.
- Value
- ₹103.2 Cr
- Execution
- Within 3 months